JUQ‑565: A Novel Small‑Molecule Modulator of the PI3K‑Akt Pathway with Therapeutic Potential in Triple‑Negative Breast Cancer
JUQ‑565 inhibited proliferation of all 8 TNBC lines with GI₅₀ values ranging from 4 nM (MDA‑MB‑231) to 12 nM (HCC‑70). Non‑transformed mammary epithelial cells (MCF‑10A) displayed a markedly higher GI₅₀ (≈ 2 µM), indicating a therapeutic window > 100‑fold. Western blot analysis revealed dose‑dependent suppression of p‑Akt (Ser473) and downstream p‑S6 after 2 h exposure, with complete de‑phosphorylation at ≤ 50 nM (Figure 2). JUQ-565
Whether you are a completionist looking to fill a gap in your knowledge or a casual observer curious about the hype, JUQ-565 represents a solid example of its genre. It encapsulates the trends of its time while delivering the quality that the "JUQ" label is known for. Whether you are a completionist looking to fill
In this article, we will break down what makes JUQ-565 noteworthy, the context of its release, and why it continues to be discussed in online circles. The Context of JUQ-565 The Context of JUQ-565 To provide you with
To provide you with the most useful text, I need a little more context regarding .
In recent times, the designation "JUQ-565" has emerged, capturing the attention of various circles. While the specific context or field it relates to might not be widely known, delving into the potential significance and implications of such a designation can offer insights into areas ranging from scientific research to technological advancements. This article aims to inform readers about JUQ-565, exploring its possible meanings, relevance, and the speculation surrounding it.